Mereo BioPharma Group plc
MREOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. At a $48.8M market cap, Mereo BioPharma Group plc ranks as a micro-cap company within healthcare. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Market Cap
$48.8M
Beta
0.29
P/E (TTM)
—
P/E (Fwd)
-8.04
EPS (TTM)
$-0.20
EPS (Fwd)
$-0.04
ROE
-75.9%
ROA
-41.2%
Cash
$36.2M
Total Debt
$0
Free CF
-$14.4M
52W Change
-82.6%
Annual Financials
Cash vs Debt
Where MREO stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, MREO finished 42.59% below its 150-day moving average ($0.54) and 65.17% below its 200-day moving average ($0.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MREO overbought or oversold?
At the July 15, 2026 close, MREO's RSI(14) was 47.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Mereo BioPharma Group plc reports $36.2M in cash and $0 in total debt. Free cash flow is running at -$14.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -75.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.29 suggests MREO is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Mereo BioPharma Group plc's trajectory.